Key result
Review details the mechanisms and severity of drug-drug interactions between DOACs and AADs in AF.
Why the study?
The effect of drug-drug interactions between direct oral anticoagulants and antiarrhythmic drugs has not been fully elucidated, which is important for providing safe and effective therapy in patients with AF.
What are the mechanisms and severity of drug-drug interactions between direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation?
What are the mechanisms and severity of drug-drug interactions between direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation?
Understanding the drug-drug interactions between direct oral anticoagulants and antiarrhythmic drugs is crucial for providing effective and safe therapy in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Potential interactions warrant caution with DOACs and antiarrhythmics in AF; review extends mechanistic insights but leaves clinical outcomes open.
The use of direct oral anticoagulants minimized the risks associated with vitamin K antagonist (warfarin) therapy. Currently, direct oral anticoagulants have priority over warfarin for the prevention of thromboembolic events in patients with atrial fibrillation and a number of other conditions requiring anticoagulant therapy. Direct oral anticoagulants along with antiarrhythmic therapy are the accepted strategy for atrial fibrillation treatment. At the same time, the effect of drug-drug interactions (DDI) between direct oral anticoagulants and antiarrhythmic drugs, which have common points of metabolic application, has not been fully elucidated. In order to provide effective and safe anticoagulant and antiarrhythmic therapy in patients with AF, it is important to understand the mechanisms and severity of DDI of direct oral anticoagulants and antiarrhythmic agents. This review discusses the issues of DDI of direct oral anticoagulants and antiarrhythmic drugs used to treat atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Tatarsky et al. (2021) conducted a review in Atrial fibrillation. Direct oral anticoagulants and antiarrhythmic drugs was evaluated. This review discusses the mechanisms and severity of drug-drug interactions between direct oral anticoagulants and antiarrhythmic drugs used to treat atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: